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Dr RonaldWebb (Oakland, Calif): First of all, I would like to
thank the program committee for askingme to review this paper. It
forced me to review a little bit of biochemistry. Second of all, I
would like to thank Drs Dilley and DeLaria for having this meeting
at what I think has been an exceptionally nice venue, and I would
also like to thank Dr Killewich for communicating with me by
e-mail with this paper several weeks ago. It is also interesting this is
the first day in Washington for peripheral arterial disease to discuss
a paper with regards to amino acids and peripheral arterial disease.
There are really three things that have had level I evidence that
improved claudication distance, and one has been smoking cessa-
tion, one has been supervised exercise, and the third has been
Pletal.
There are other drugs that we are using now in the office that
I think help us with the management of the claudicant. The statin
drugs of interest have been shown to actually lower the C-reactive
protein which you know is an inflammatory index of carotid artery
disease. Plavix has improved the claudication distance with which I
was not aware. The (CAPRI) study actually shows a stronger
benefit in those people with peripheral vascular disease than it does
in preventing TIA. I think most of us now are also starting patients
on ACE inhibitors and beta-blockers.
The question this paper has asked is, will amino acid supple-
ments help the claudicant? I think this is an interesting paper. I ride
bicycles a lot. There is a cult amongst bicycle riders. They have
recovery drinks they take. I ride with bicycle riders who actually
take insulin injections to speed up the entry of amino acids into
their mitochondria. I think Floyd Landis is a Southern Californian
and Barry Bonds is a Northern California.
There are 12 nonessential amino acids, which can be manu-
factured from the eight dietary essential amino acids inside the
body. There are three branch change amino acids, which arecycle is interesting. This is anaerobic muscle metabolism. After the
liver and the muscle utilize glucose, they begin to use amino acids.
The byproducts of this, lactate and pyruvate, probably cause a lot
of the muscle pain that we have when we experience claudication,
but there are also other side effects of that.
Carnitine is an interesting protein because it facilitates the
rapid exchange of these amino acids into the mitochondria. Car-
nitine has been used in drinks in Europe to try to improve claudi-
cation. Vanderbilt studied an intradialytic parenteral nutrition
where they put people on dialysis on amino acid infusions during
dialysis and have demonstrated increased strength, walking ability
and just well-being after doing this during this opportunity three
times a week on 4 hours of dialysis. I did find one study that
demonstrated insulin does not stimulate protein synthesis within
the muscle. There is evidence that a continuous infusion of phe-
nylalanine improves muscle protein synthesis after endurance run-
ning.
Having said all this, claudication is not just simply a reduction
in blood flow to themuscle mass. There are events that occur at the
moment of claudication which involve endothelial dysfunction.
There are free radicals produced. There are acute-phase proteins
produced. There is another factor called cellular adhesion mole-
cules. There are differences in nitric oxide availability, which is also
affected by arginine levels. Acetyl-carnitine is a breakdown of
carnitine, which increases dramatically at the moment of claudica-
tion that may be causing some of the muscle pain that we get
during claudication, and then, of course, there is lactic acid.
In addition, claudication is probably more importantly a
marker of other symptoms of peripheral vascular disease or periph-
eral arterial disease. It has been suggested that 40% of people die or
have a stroke within 5 years after having had claudication found as
a marker, and one study said even as high as 60% will have coronary
artery disease within 5 years.
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tion can increase the muscle mass of claudicants. However, this
paper does not document that the pain of claudication or the
distance of claudication improved with nutritional supplementa-
tion. Will Hiatt at the University of Colorado has shown an
increase in treadmill distance after giving 2 grams of carnitine twice
daily orally.
My questions to the author are, one, what mixture of essential
acids and nonessential amino acids do you feel could improve the
exercise tolerance of a claudicant? Number two, why did you
choose phenylalanine rather than leucine, arginine, or carnitine for
this study? And what type of study would you design to prove you
could increase claudication distance—a 6-minute walk test, gaited
treadmill exercise, peak blood flow with plethysmography, or
Doppler indices?
I appreciate having the opportunity to discuss this paper.
Dr Lois Killewich: Thank you very much, Dr Webb, for your
comments. I guess I have an advantage here; the questions are
right here up where I can see them. What mixture of essential and
nonessential amino acids do you feel could improve the exercise
tolerance of claudicants? Well interestingly I did not really go over
it in my paper, but the work on essential amino acids was started by
a large group of physiologists in Galveston headed by Dr Wolfe,
whom you alluded to in your comments. They have studied in the
past essential versus nonessential amino acids, and they found that
the nonessential amino acids, at least in healthy elderly, had no
benefit. That is why in my study I have used essential amino acids
only and the studies we plan to do in the future will be using only
essential amino acids.
Why we chose phenylalanine rather than a different stable
isotope basically has to do with the cost, the availability, and the
fact that, for example, the lucine stable isotope is oxidized in
muscle, and so if you are going to use that as your tracer for protein
synthesis, you have to do a lot of additional calculations and
measurements in order to account for the oxidation. It is really just
an ease of use of the isotope.
And what type of study would I design to prove that I could
increase claudication distance? Well, the study that we are starting
now, we are going to give amino acid supplements to claudicants
for a 16-week period and our end points are going to include both
treadmill testing and the 6-minute walk test. The 6-minute walk
test is a very simple test of claudication, which actually was devel-
oped by Andy (Gardner), and it involves having a patient walk in a
hallway between cones. There is no treadmill, no graded treadmill,
or constant load treadmill, and it has been validated in the sense
that it is thought to reflect walking during daily activities of living
more appropriately. We will be using that test. We will be using
treadmill testing, and we will also be using various measurements
of functional capacity.
Dr George Andros (Encino, Calif): I had a few questions.
Isn’t this basically a pharmacology investigation?
Dr Killewich: Okay.
Dr Andros: And in most pharmacology investigations there
are at least two essential criteria for the assessment of the drug; one
is a time curve for the appearance of the effect, and a second is a
dose-response curve. Have you inquired into these?
Several years ago, we were involved with the use of a magnetic
resonance flowmetry technique and we had a lengthy discussion
with Gene Strandness about whether or not blood flow at rest in
claudicants is increased or decreased or the same, and our data
showed that blood flow as compared to calf plethysmography was
decreased in claudicants at rest. He felt that it was not decreased,
and we had many discussions on this. So, there is a fundamental
question here: is blood flow in claudicants decreased or normal?
Then there is the other question of biopsy distortion. In my
previous life as a biophysicist, I did many animal studies on biopsydistortion of blood flow and we found that is a significant effect on
blood flow as you do serial biopsies of muscle structure.
The final point that I had was that I think there is a missing
control group. You have a control group that is given phenylala-
nine and a normal group. Do you have a control group in which
you have claudicants with their presumed reduced blood flow who
received phenylalanine and those who received some other nones-
sential amino acid or some other control group within the group
that you are studying so that the control group I believe should be
two different claudicant groups rather than a claudicant and a
control group.
DrKillewich:Thank you very much, Dr Andros. Yes, we have
done the time study and also the dose-response study, and we have
done those at a couple different doses of amino acids. We did it at
8 grams of essential amino acids. We did it at 15 grams. We have
also done nonessential amino acids and amino acid and carbohy-
drate combinations. Yes, we did do those and we found that the
most benefit was associated with the 15-gram essential amino acid
in this particular time duration.
As far as is blood flow reduced at rest, I do not really know the
answer to that question other than what we did in this study and
that is we measured calf blood flow using strain gauge and that is a
pretty standard technique which is used in the literature. A lot of
studies have used that technique and so all I can say is that we did
find it was reduced at rest in these patients.
As far as biopsy distortion of blood flow, I think the key point
there is that we measured blood flow at the end of the protocol
after we had already done three muscle biopsies and so you could
make the argument that—I think it is what you are saying—the
biopsies distorted the blood flow measurement which we did after
the biopsies, but in fact, when we started doing this we were doing
blood flow measurements at the beginning of the protocol and we
did them twice, once at the beginning and once at the end. We did
not find any difference and so we stopped doing them at the
beginning because it was too cumbersome for the overall protocol.
Finally, I would have to say that you are correct; we do not
have the control group where we gave them a different amino acid.
Dr Niren Angle (San Diego, Calif): Beautiful paper. I have a
quick question for you. If you look in the exercise physiology
literature there is a fair amount of data that says that most protein
does not matter. It is the branch chain amino acid supplementa-
tion, the isolucine, the valine, and the lucine, and I know there is a
fair amount of controversy about that, but could you comment on
using just branch chain amino acids instead of essential.
Number two, have you entertained doing this with having
them do resistance training or exercising and then supplementing
them within a few hours or within an hour of exercise because that
seems to increase muscle mass much more than the standard
supplementation of protein at any variable time during the day.
Thank you.
Dr Killewich: Thank you very much. I cannot say that we
have actually studied branch chain amino acids and so I cannot say
whether they would have the same benefit that our particular
formulation of essential amino acids has but you certainly have a
valid point there.
As far as using exercise training, in particular endurance train-
ing, as well as amino acids; yes, we have contemplated doing that.
We have done some studies on that, not in claudicants, and we
would like to do that in the future. Other investigators in
Dr Wolfe’s group have shown that the combination of endur-
ance exercise and oral amino acids will actually improve your
muscle protein synthesis and your strength greater than just
amino acids alone. Needless to say, the question is always raised
with claudicants as to how much they can exercise, but I chose
amino acids initially because I felt that this might be more
widely applicable.
